Slaskie Centrum Chorob Serca W Zabrzu
- Address
- lock Available on a paid plan
Slaskie Centrum Chorob Serca W Zabrzu - Advanced Cardiovascular Research Center
Slaskie Centrum Chorob Serca W Zabrzu (Silesian Center for Heart Diseases in Zabrze) is a leading cardiovascular research institution specializing in comprehensive clinical trials across the full spectrum of cardiac conditions. The center demonstrates particular expertise in heart failure management, interventional cardiology, and cardiomyopathy research, conducting innovative studies that address both acute cardiac events and chronic cardiovascular disease prevention.
- Acute myocardial infarction treatment and secondary prevention, including iron deficiency management and lipid-lowering therapies
- Heart failure with reduced and mid-range ejection fraction, including novel ARNI therapy and cardioprotection strategies
- Structural heart disease and complex cardiomyopathies, including hypertrophic and arrhythmogenic cardiomyopathy
- Advanced interventional procedures and device-based therapies, particularly left atrial appendage closure for atrial fibrillation
The center's research portfolio reflects a comprehensive approach to cardiovascular care, ranging from cardio-oncology studies preventing treatment-related cardiotoxicity to investigations of inflammatory myocarditis and immunosuppressive therapies. With expertise in advanced cardiac imaging techniques including cardiac MRI, the facility evaluates novel therapeutic interventions across diverse patient populations, including those with end-stage renal disease and transplant recipients. This breadth of research underscores the center's commitment to advancing evidence-based cardiovascular medicine and improving outcomes for patients with complex cardiac conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 27 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
- 1Agencja Badań Medycznych4active
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Agencja Badań Medycznych4trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Slaskie Centrum Chorob Serca W Zabrzu
lock Showing 1 of 25 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged ≥2 to <18 years with Pulmonary Arterial Hypertension | Actelion Pharmaceuticals Ltd. | Phase III | Not Recruiting | Feb 2020 | — |
IMP list
lock Showing 1 of 27 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 3 | Unknown | 2025-11-24 | 2025-11-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.